These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15448034)

  • 1. Novel antiangiogenic therapies for renal cell cancer.
    Gordon MS
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
    Ebbinghaus SW; Gordon MS
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
    Choueiri TK; Bukowski RM; Rini BI
    Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease.
    Sardi I; Sanzo M; Giordano F; Buccoliero AM; Mussa F; Aricò M; Genitori L
    Pediatr Blood Cancer; 2009 Sep; 53(3):464-7. PubMed ID: 19415739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
    Board RE; Thistlethwaite FC; Hawkins RE
    Cancer Treat Rev; 2007 Feb; 33(1):1-8. PubMed ID: 17071006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to angiogenesis inhibitors in renal cell carcinoma.
    Tamaskar I; Dhillon J; Pili R
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
    Jennens RR; Rosenthal MA; Lindeman GJ; Michael M
    Urol Oncol; 2004; 22(3):193-6. PubMed ID: 15271314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
    Audenet F; Rouprêt M; Méjean A
    Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents for the treatment of renal cell carcinoma.
    Tian GG; Dawson NA
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):546-54. PubMed ID: 12113087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell cancer.
    Hutson TE; Figlin RA
    Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?
    Soulières D
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complexity of tumor vasculature in clear cell renal cell carcinoma.
    Qian CN; Huang D; Wondergem B; Teh BT
    Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
    Schrader AJ; Varga Z; Pfoertner S; Goelden U; Buer J; Hofmann R
    BJU Int; 2006 Mar; 97(3):461-5. PubMed ID: 16469008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.